Osteosarcopenia in fracture patients was associated with unadjusted differences in selected gut microbial taxa and fecal metabolites within a broadly shared microbial community, yielding hypothesis-generating findings that require validation in larger independent cohorts before clinical or biomarker application.
Key Findings
Results
Neither α-diversity nor overall β-diversity showed marked differences across the four musculoskeletal phenotypes, suggesting broad community replacement was not observed.
69 fracture patients aged ≥50 years were classified into four phenotypes: Normal (n=18), isolated low bone mass/Bone (n=18), isolated sarcopenia/Muscle (n=19), and osteosarcopenia/Both (n=14)
Fecal samples were analyzed using shotgun metagenomics and untargeted metabolomics, yielding paired multi-omics data for 52 participants
The absence of marked α- and β-diversity differences indicates that osteosarcopenia is not associated with wholesale shifts in gut microbial community structure
Findings suggest that taxon-specific or functional differences, rather than broad community-level changes, characterize the condition
Results
A multi-stage, multi-method strategy identified a 17-species consensus feature set associated with differences among musculoskeletal phenotypes.
The consensus feature set was derived using a multi-stage, multi-method analytical strategy applied to shotgun metagenomic data
Taxonomic patterns were consistent with a candidate fiber/short-chain fatty acid (SCFA)-associated module
Exploratory microbe-metabolite correlations suggested a candidate lipid/sterol-associated module
The 17-species set represents convergent findings across multiple analytical methods rather than a single statistical approach
Results
Exploratory microbe-metabolite correlations identified a candidate lipid/sterol-associated module linked to osteosarcopenia, including associations between Firmicutes bacterium CAG:24053_14 and putatively annotated cholesterol and N-acylethanolamines.
Correlations were detected between Firmicutes bacterium CAG:24053_14 and fecal metabolites putatively annotated as cholesterol and N-acylethanolamines
N-acylethanolamines are bioactive lipid mediators with known roles in inflammation and metabolic regulation
Cholesterol and its derivatives have established roles in bone and muscle biology, providing biological plausibility for these associations
These findings are described as exploratory and hypothesis-generating, not confirmatory
Results
The Bone group (isolated low bone mass) had significantly higher mean age compared to other phenotype groups.
The Bone group had the highest mean age at 66.6 ± 9.46 years
Mean ages of the Normal, Muscle, and osteosarcopenia groups ranged from 60.6 to 61.8 years
The overall difference in age across groups was statistically significant (p = 0.029)
Sex, BMI, lifestyle factors, and comorbidities did not differ significantly across the four phenotype groups
Results
Osteosarcopenia was associated with differences in selected gut microbial taxa and fecal metabolites that are consistent with both a fiber/SCFA-associated module and a lipid/sterol-associated module.
The fiber/SCFA-associated module was identified based on taxonomic patterns among the 17-species consensus feature set
SCFAs are well-established modulators of bone and muscle metabolism, providing mechanistic plausibility
The lipid/sterol-associated module was identified through exploratory microbe-metabolite correlation analyses
The two candidate modules together suggest potentially distinct microbial functional pathways associated with osteosarcopenia
Methods
The study design was a single-center, prospective cross-sectional study of fracture patients aged ≥50 years in China, with paired metagenomics and metabolomics data available for 52 of 69 enrolled participants.
Study enrolled 69 fracture patients but paired multi-omics data were available for 52 participants
Participants were classified into four phenotypes: Normal (n=18), Bone (n=18), Muscle (n=19), and Both/osteosarcopenia (n=14)
Shotgun metagenomics and untargeted metabolomics were performed on fecal samples
Authors explicitly state findings are hypothesis-generating and require validation in larger independent cohorts before clinical or biomarker application
What This Means
This research suggests that osteosarcopenia — a condition where a person has both low bone mass and loss of muscle mass simultaneously — is associated with specific differences in the gut microbiome (the community of microbes living in the intestines) and the chemical compounds those microbes produce. The researchers studied 69 Chinese fracture patients aged 50 and older, dividing them into four groups based on whether they had normal bone and muscle health, only low bone mass, only sarcopenia (muscle loss), or both conditions together. By analyzing stool samples with advanced genomic and chemical profiling techniques, the team identified 17 bacterial species whose presence differed across groups, as well as patterns suggesting that gut bacteria involved in producing short-chain fatty acids (from dietary fiber) and lipid/sterol metabolism may be particularly relevant to osteosarcopenia.
Interestingly, the overall diversity and composition of the gut microbial community did not look dramatically different between groups — meaning osteosarcopenia was not associated with a wholesale replacement of gut bacteria. Instead, subtler differences in specific species and their metabolic outputs were detected. One notable finding was a correlation between a specific Firmicutes bacterium and fecal cholesterol and N-acylethanolamines (bioactive fat molecules), hinting at possible gut-mediated lipid pathways that could influence bone and muscle health simultaneously.
This research suggests there may be gut microbiome and metabolite signatures that distinguish osteosarcopenia from isolated bone or muscle problems, which could eventually inform new diagnostic or therapeutic approaches. However, the authors are careful to note that this was a small, single-center study and the findings are hypothesis-generating only. Larger studies in independent populations are needed before any of these microbial or metabolite markers could be considered for clinical use.
Li M, Zhao X, Zhang B, Cao R, Wang Z, Huang Z, et al.. (2026). Gut microbiome-metabolome signatures of osteosarcopenia in fracture patients in China.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1863988